Topics:
Pediatric Oncology • Rheumatology • COVID-19 • Hematology • Pediatric Hematology • Benign Hematology • General Rheumatology • COVID-19 virus
Is rituximab for refractory ITP contraindicated in the setting of an active COVID infection, particularly in a patient with asymptomatic COVID?
Answer from: at Academic Institution
Given that we would delay rituximab treatment for many active infections, I would recommend that we apply the same restrictions. I would hold the rituximab for ten days after covid test confirmation.
Sign in or Register to read more
Answer from: at Community Practice
I would delay antibody in view of infection.